You are here: Industry Insights > Pharma in China

News List

A New Favorite in the Medical World: Epigenetic Drugs PharmaSources/Yefenghong
August 21, 2019
Epigenetics was coined by Conrad Waddington, a British developmental biologist, in the 1950s to describe the interactions between the environment and the genes in the developmental process...
“Upstar” against Breast Cancer—CDK 4/6 Inhibitors: Which has the Biggest Potential among the Three? PharmaSources/Dopine
August 20, 2019
Targeted therapies have played an increasingly important role in tumor treatment in recent years.
Overseas Sight: The Fast-rising South Korean Biopharmaceutical Industry PharmaSources/zhulikou431
August 15, 2019
As the global pharmaceutical industry flourishes, the biopharmaceutical area has also made significant progress. We can see how active the two South Korean pharmaceutical enterprises...
Why Edaravone of Mitsubishi Tanabe is Excellent? PharmaSources/1℃
August 14, 2019
Edaravone of Mitsubishi Tanabe was approved for marketing in China on July 31, 2019, with the acceptance No.: JXHS1900047 and indication of amyotrophic lateral sclerosis (ALS).
The “miracle drug” metformin has no anticancer efficacy? PharmaSources/Yefenghong
August 07, 2019
Three studies at the ASCO Meeting revealed surprising results
Dual tailwinds for the injection export of Chinese pharmaceutical enterprises to the U.S. PharmaSources/Xiaoyaowan
August 06, 2019
Pharmaceutical products produced in China with the same production line and approved for marketing in the EU, Japan, or the U.S. can be deemed as passing the consistency evaluation after the review and approval by the Consistency Evaluation Office.
A Review of the Injection Varieties of the Top 4 Chinese Pharmaceutical Enterprises Exporting to the U.S. PharmaSources/Xiaoyaowan
August 06, 2019
China’s export of western medicine products reached USD36.883 billion in 2018, wherein, the export of western medicine preparations reached USD4.100 billion, growing by 18.64% year on year.
Biologics or small molecule drugs for rare disease treatment? It is a question PharmaSources/Miling
July 31, 2019
To both patients and pharmaceutical practitioners, it is a question as to whether to choose biologics or small molecule drugs for rare disease treatment, since the prices are sky-high.
Enbrel and Its Patent Layout: The Period of Market Exclusivity until 2029! PharmaSources/zhixing
July 30, 2019
Patents are fortresses of new drugs. The patent layout of Enbrel is quite impressive: the span from the first application in 1995 to the patent expiration in 2029 reaches 34 years.
Hyaluronic Acid Used in the Most Popular Cosmetic Medicine Micro-Plastic Surgery Items PharmaSources/Xiaoyaowan
July 29, 2019
Size of the cosmetic medicine market in China reached RMB122 billion in 2018, making it the second largest cosmetic medicine market in the world.